What is purpura fulminans?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is Purpura Fulminans

Purpura fulminans is a life-threatening hematological emergency characterized by rapidly progressive skin necrosis, disseminated intravascular coagulation (DIC), and thrombotic occlusion of small and medium-sized blood vessels that can rapidly progress to multi-organ failure and death. 1, 2

Clinical Presentation and Pathophysiology

Purpura fulminans manifests as:

  • Rapidly spreading purpuric skin lesions that progress to hemorrhagic necrosis and gangrene 3, 4
  • Disseminated intravascular coagulation with consumption of clotting factors and platelets 2, 3
  • Thrombotic occlusion of small and medium-sized blood vessels leading to tissue ischemia 1, 3
  • Multi-organ failure if untreated, with patients often dying from overwhelming thrombosis rather than septic shock 1, 2

The fundamental pathologic defect is failure of the anticoagulant protein C pathway, leading to uncontrolled microvascular clotting and loss of protein C-mediated cytoprotective effects that are vital for survival in sepsis 1.

Three Distinct Etiologic Categories

1. Infection-Associated (Acute) Purpura Fulminans

  • Most common form, complicating severe bacterial sepsis (particularly meningococcemia, pneumococcemia) and rarely viral infections 1, 2, 3
  • Presents with high fever, hypotension, purpuric ecchymosis, and rapid progression over hours to days 4, 5
  • Associated with severe acquired protein C deficiency during acute sepsis 2, 3
  • Can be confused with Rocky Mountain spotted fever, which also presents with cutaneous necrosis and gangrene but has a longer prodrome with fever, headache, and myalgia before rash development 6

2. Congenital (Neonatal) Purpura Fulminans

  • Presents in the newborn period as the most dramatic manifestation of homozygous protein C deficiency 6
  • Results from inherited severe deficiency of natural anticoagulant proteins (protein C or protein S) 3
  • Requires lifelong management with protein C replacement, anticoagulation, or liver transplantation 6, 7

3. Autoimmune (Post-Infectious) Purpura Fulminans

  • Occurs as an autoimmune response to otherwise benign childhood infections (typically varicella, scarlet fever) 3
  • Develops days to weeks after the initial infection 3

Mortality and Morbidity

  • Extremely high mortality rate if not recognized and treated immediately 2, 3
  • Patients who survive past 24-72 hours often die from complications of unchecked thrombosis rather than shock 1
  • Survivors typically require multiple amputations of involved extremities and experience severe scarring in affected areas 1, 2, 5
  • In one series, 24 amputations were performed on 12 patients who survived the acute phase 5

Critical Diagnostic Features

The diagnosis requires recognition of:

  • Rapidly progressive purpuric skin lesions with necrosis 3, 4
  • Laboratory evidence of DIC with thrombocytopenia, prolonged PT/PTT, low fibrinogen, elevated D-dimer 2, 3
  • Severe acquired protein C deficiency (in infection-associated cases) or congenital deficiency (in neonatal cases) 1, 2, 3
  • Clinical context of severe sepsis, newborn with family history, or recent childhood infection 3

Management Principles

Immediate treatment is essential and includes:

  • Aggressive treatment of underlying infection with appropriate antimicrobials 2, 3
  • Protein C replacement therapy (protein C concentrate or fresh-frozen plasma) to restore anticoagulant function 7, 8, 2
  • Therapeutic anticoagulation to prevent further thrombosis 2, 3
  • Robust transfusion support aimed at correcting acquired deficiencies in natural anticoagulant proteins 2
  • Avoidance of vasopressors when possible, as adrenergic agents worsen ischemic changes 5

For congenital cases, protein C replacement is superior to anticoagulation alone for treating skin lesions, with non-necrotic lesions healing in a median of 4 days and necrotic lesions in a median of 11 days 7, 8.

Delayed surgical debridement (up to 3 weeks) is recommended to allow ischemic tissue to fully demarcate before amputation 5.

References

Research

Purpura fulminans: recognition, diagnosis and management.

Archives of disease in childhood, 2011

Research

Purpura fulminans.

The Journal of hand surgery, 1990

Research

Purpura fulminans. Medical, surgical, and rehabilitative considerations.

Clinical orthopaedics and related research, 1985

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Congenital Purpura Fulminans

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.